烟酰胺核糖作为青光眼神经保护治疗:随机双盲安慰剂对照试验研究方案
本研究为随机、双盲、安慰剂对照、平行组、多中心试验,纳入125例原发性开角型青光眼患者,随机接受300 mg烟酰胺核糖或安慰剂治疗24个月,主要结局为24个月内视网膜神经纤维层变薄速率,以评估烟酰胺核糖的神经保护作用。
要点
- 尽管降低眼压可延缓青光眼视神经变性,许多患者仍出现进行性视力丧失,目前尚无有效的神经保护治疗。
- 本研究假设烟酰胺核糖治疗患者的进行性视网膜神经纤维层变薄速率较安慰剂组慢。
- 主要结局为24个月内视网膜神经纤维层变薄速率,采用线性混合模型比较组间差异。
核心结论
- 本研究旨在探讨烟酰胺核糖是否可延缓原发性开角型青光眼患者的视神经变性,假设其可减慢进行性视网膜神经纤维层变薄速率。
研究设计与样本
- 随机、双盲、安慰剂对照、平行组、多中心研究,纳入125例原发性开角型青光眼患者。
- 患者随机接受300 mg烟酰胺核糖或安慰剂治疗24个月。
- 在基线、1个月、4个月及之后每2个月直至24个月进行临床检查、视网膜神经纤维层光学相干断层扫描成像和视野检查。
关键数值与推荐
- 主要结局指标为24个月内测量的视网膜神经纤维层变薄速率。
- 次要结局指标包括:至视野进展时间、至进行性视网膜神经纤维层/神经节细胞内丛状层变薄时间、24个月内(研究神经保护)和1个月内(研究神经增强)视野敏感度变化速率。
- 采用线性混合模型比较治疗组间视网膜神经纤维层变薄速率和视野敏感度下降速率;采用Cox比例风险模型进行生存分析,比较治疗组间从基线至视野进展时间和从基线至进行性视网膜神经纤维层/神经节细胞内丛状层变薄时间的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whereas lowering the intraocular pressure (IOP) can slow optic nerve degeneration in glaucoma, many patients with glaucoma continue to develop progressive loss in vision despite a significant reduction in IOP. No treatment has been shown to be effective for neuroprotection in glaucoma. We set out to conduct a randomized controlled trial to investigate whether nicotinamide riboside (NR), a nicotinamide adenine dinucleotide precursor, is effective to slow optic nerve degeneration in patients with primary open-angle glaucoma (POAG). We hypothesize that patients treated with NR have a slower rate of progressive retinal nerve fiber layer (RNFL) thinning compared with those treated with placebo. METHODS: This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study including 125 patients with POAG. Patients will be randomized to receive 300 mg NR or placebo for 24 months. Clinical examination, optical coherence tomography imaging of the RNFL, and visual field (VF) test will be performed at the baseline, 1 month, 4 months, and then at 2-month intervals until 24 months. The primary outcome measure is the rate of RNFL thinning measured over 24 months. The secondary outcome measures include (1) time to VF progression, (2) time to progressive RNFL/ganglion cell inner plexiform layer (GCIPL) thinning, and (3) the rate of change of VF sensitivity over 24 months (to investigate neuroprotection) and 1 month (to investigate neuroenhancement). The rates of RNFL thinning and VF sensitivity decline between treatment groups will be compared with linear mixed modeling. Survival analysis will be performed to compare the differences in time from baseline to VF progression and time from baseline to progressive RNFL/GCIPL thinning between treatment groups using Cox proportional hazards models. DISCUSSION: Outcome measures in glaucoma neuroprotection trials have been centered on the detection of VF progression, which may take years to develop and confirm. In addition to addressing whether NR has a neuroprotective/neuroenhancement effect in glaucoma patients, this study will demonstrate the feasibility of studying neuroprotection in a relatively short trial period (24 months) by comparing the rates of progressive RNFL thinning, a more reproducible and objective outcome measure compared with VF endpoints, between treatment groups. TRIAL REGISTRATION: Chinese Clinical Trial Registry 1900021998.
引用
- Leung CKS, Ren ST, Chan PPM, et al. Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. Trials. 2022. PMID: 35039056. doi:10.1186/s13063-021-05968-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。